Pharmaceutical Executive Daily: Source Denies AstraZeneca-Bristol Myers Squibb Merger Talks
Aug 05, 06:45 PM
Share
Subscribe
In today's Pharmaceutical Executive Daily, a senior source denies reports of merger talks between AstraZeneca and Bristol Myers Squibb, CSPC Pharmaceutical and AstraZeneca form a joint venture for biologics manufacturing in China, and a feature examines how U.S. Patent and Trademark Office policy changes are slowing patent challenges for generic and biosimilar drugmakers.
